Therefore, the finding that upon exposure to dabrafenib PTTG1 expression was markedly impaired only in melanoma cells sensitive to the drug and that this molecular event contributed to dabrafenib-induced inhibition of cell proliferation and invasiveness, prompt us to conduct an exploratory study to assess whether the PTTG1 protein could be detected also in plasma of melanoma patients and whether changes in circulating PTTG1 levels occurred during targeted therapy and were related to patient response. The gene discussed is PTTG1; the disease is melanoma.